
Acromegaly Program in Pharmaceutical Benefits Scheme (PBS) 012-18051100

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

This document outlines details of the Pharmaceutical Benefit Scheme
(PBS) subsidised pasireotide and pegvisomant for patients with
acromegaly (ACRO).

On this Page:

Acromegaly and listing dates

Acromegaly is a condition caused by excessive growth hormone.

Listing dates are as follows:

-   pasireotide - 1 September 2016
-   pegvisomant - 1 September 2017

See Written Authority Required Drugs for further information.

Enquiries

Transfer enquiries about prescription arrangements to the Complex Drugs
Programs team and choose the team relevant to the condition treated.

The Resources page contains a quick reference guide, links to
restriction and item codes, contact details, application forms, and the
Pharmaceutical Benefits Scheme (PBS) and Services Australia websites.

Related links

Written Authority Required Drugs

Processing Written Authority Required Listings

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA)

                                   

-   Services Australia ABN 90 794 605 008 
